Dr. Yang, Pan-Chyr
Joint Appointment Research Fellow
Academician, Academia Sinica
- 02-27899149 (Lab) (Room No: 511)
- 02-27858594 (Fax)
-
Specialty:
- Cell and Molecular Biology
- Cancer genomics
Education and Positions:
M.D., Ph.D. National Taiwan University
Highlight Detail
Potential therapeutics using tumor-secreted lactate in nonsmall cell lung cancer
Dr. Yang, Pan-Chyr
Drug Discovery Today, Jul 26, 2021
Targeted-therapy failure in treating nonsmall cell lung cancer (NSCLC) frequently occurs because of the emergence of drug resistance and genetic mutations. The same mutations also result in aerobic glycolysis, which further antagonizes outcomes by localized increases in lactate, an immune suppressor. Recent evidence indicates that enzymatic lowering of lactate can promote an oncolytic immune microenvironment within the tumour. Here, we review factors relating to lactate expression in NSCLC and the utility of lactate oxidase (LOX) for governing therapeutic delivery, its role in lactate oxidation and turnover, and relationships between lactate depletion and immune cell populations. The lactate-rich characteristic of NSCLC provides an exploitable property to potentially improve NSCLC outcomes and design new therapeutic strategies to integrate with conventional therapies.